Enabling exploitation of novel reagents and assays (EnRgy) to target the inhibition of peptidoglycan biosynthesis

Lead Research Organisation: University of Warwick
Department Name: School of Life Sciences

Abstract

Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.

Technical Summary

N/A

Planned Impact

N/A
 
Description Knowledge transfer from the pharmaceutical antibiotic discovery industry to academia and vice versa. More effective approaches to industry
Exploitation Route Additional support for academic and industrial leave and engagement
Sectors Education,Pharmaceuticals and Medical Biotechnology

 
Description They have informed global pharma, given them new insight and new approaches for antibiotic discovery, including the development of new screening capabilities in the form of reagents and assays
First Year Of Impact 2014
Sector Aerospace, Defence and Marine,Education,Pharmaceuticals and Medical Biotechnology
Impact Types Economic

 
Description Accelerate CHNUK AMR discovery: Establishing joint China/UK training and research platforms enabling highthroughput fragment based inhibitor discovery
Amount £1,000,000 (GBP)
Funding ID MR/P007503/1 
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 06/2016 
End 05/2019
 
Description Coventry General Charities
Amount £157,000 (GBP)
Organisation General Charity of the City of Coventry 
Sector Charity/Non Profit
Country United Kingdom
Start 03/2018 
End 09/2022
 
Description Coventry General Charities
Amount £40,000 (GBP)
Organisation General Charity of the City of Coventry 
Sector Charity/Non Profit
Country United Kingdom
Start 01/2014 
End 01/2015
 
Description MRC AMR theme 1 collaboration award
Amount £3,200,000 (GBP)
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 09/2015 
End 09/2020
 
Description Wellcome Trust Innovation Award
Amount £100,000 (GBP)
Funding ID 109676/Z/15/Z 
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 06/2016 
End 06/2017
 
Description Astra Zeneca global screening platform 
Organisation AstraZeneca
Country United Kingdom 
Sector Private 
PI Contribution Knowledge transfer, biological insight and assay development
Collaborator Contribution Advice, knowledge transfer, training and access to high throughput screening platforms and chemical libraries
Impact Novel assay development and assay validation Hit screening underway
Start Year 2013
 
Description Entasis collaboration 
Organisation Entasis Therapeutics
Country United States 
Sector Private 
PI Contribution Biochemistry and assay development
Collaborator Contribution Assay validation and hit characterisation insight
Impact Successful award of Wellcome Trust Pathfinder award
Start Year 2015
 
Description Warwick Oxford Chemistry Collaboration 
Organisation University of Oxford
Department Department of Paediatrics
Country United Kingdom 
Sector Academic/University 
PI Contribution Providing underpinning assays to help inform antibiotic development approaches.....................................
Collaborator Contribution Chemistry input and design
Impact Multidisciplinary
Start Year 2014
 
Title Synthesis of peptidoglycan intermediates 
Description Optimisation of peptidoglycan pathway intermediates synthesis and purification 
IP Reference  
Protection Protection not required
Year Protection Granted 2006
Licensed No
Impact Development of a synthesis facility to provide thes eintemediates to the global research community and the fundamental platform for several UK and international peptidoglycan networks
 
Company Name Antimicrobial Discovery Solutions Ltd 
Description Reagents, assay development and services 
Year Established 2015 
Impact N/A
 
Description ANTRUK Antibiotic Research UK 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? Yes
Geographic Reach International
Primary Audience Public/other audiences
Results and Impact Establishment of new charity and new fundraising campaign

regional and national media interest
Year(s) Of Engagement Activity 2014
URL http://www.antibioticresearch.org.uk
 
Description MRC Flemming video 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? Yes
Type Of Presentation Keynote/Invited Speaker
Geographic Reach National
Primary Audience Media (as a channel to the public)
Results and Impact 100000. Short film presentation linking our current MRC funded research to the groundbreaking work by alexander Flemming

to be released later this year as part of the MRC celebrations
Year(s) Of Engagement Activity 2013
 
Description O'Neil AMR review 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Policymakers/politicians
Results and Impact In December we published our first report1
showing that infections caused by
drug-resistant pathogens are one of the biggest health problems the world faces
today. Bacteria and other pathogens have always evolved to resist the new drugs
that modern medicine uses to combat them. But in recent years the rise in drug
resistance has been a particular worry, especially the emergence of antibioticresistant
superbugs. Unless action is taken to address this huge global issue, our
conservative estimate is that it will cost the world an additional 10 million lives
a year by 2050, more than the number of people currently dying from cancer
annually. It will also have a cumulative cost of 100 trillion USD, more than one
and a half times annual world GDP today, or roughly the equivalent to losing the
UK economy from global output every year.
We now turn our attention to how this problem can be tackled. This paper is the
first in a series that works towards global and sustainable solutions. There are
many angles to the problem that we will need more time to consider. In particular,
the focus of our next paper, due to be published in the spring, will be how to
stimulate the market for companies to invest in and develop new antimicrobials and
diagnostics, which is not fully addressed here. There we will assess potential 'push'
and 'pull' incentives to encourage the development of new antimicrobial drugs,
and set out our proposals for action by policy makers. In later papers we will also
focus on important issues such as the use of antibiotics in agriculture and potential
alternatives to antimicrobials
Year(s) Of Engagement Activity 2015
URL https://amr-review.org/sites/default/files/Report-52.15.pdf
 
Description Pew Road Map for Antibiotic Discovery 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Policymakers/politicians
Results and Impact The Pew Charitable Trusts convened a multidisciplinary group of leading industry and academic experts to
identify the key scientific roadblocks to antibiotic discovery and consulted with numerous other public and
private sector stakeholders to develop a Scientific Roadmap for Antibiotic Discovery. The roadmap outlines a
concrete approach-both a scientific plan and organizational structure to support this research-that would lay a
foundation for the sustained and diversified discovery and development of new antibiotics and therapies over the
coming decades.The report's key findings show a need for:
• A targeted approach to tackle the basic scientific barriers impeding antibiotic discovery and development.
• A better understanding of how to overcome the cellular defenses of drug-resistant Gram-negative bacteria,
which cause some of the most difficult-to-treat infections.
• Generation of new chemical matter designed for antibiotic discovery.
• Tools and methodologies to evaluate promising alternatives to traditional antibiotic use.
• A framework for sharing information, expertise, and materials across the research community to foster
innovative science and spur the discovery of novel antibacterial therapies.
Year(s) Of Engagement Activity 2016
URL http://www.pewtrusts.org/~/media/assets/2016/05/ascientificroadmapforantibioticdiscovery.pdf
 
Description Radio 4 3 part drama production 
Form Of Engagement Activity A broadcast e.g. TV/radio/film/podcast (other than news/press)
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact Radio drama highlighting factors driving antibiotic resistance and global consequences - raising public awareness at the National level
Year(s) Of Engagement Activity 2017
URL http://www.bbc.co.uk/programmes/b08g7y1l
 
Description School visit 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Schools
Results and Impact 20 questions panel followed by open discussion around - what is a scientist

Invited to attend further activities by the schools career department
Year(s) Of Engagement Activity 2014
 
Description Trustee for a regional science charity MLS 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? Yes
Geographic Reach Regional
Primary Audience Public/other audiences
Results and Impact Development and distribution of new literature

Inspired fund raising
Year(s) Of Engagement Activity 2013
URL http://www.charitychoice.co.uk/medical-and-life-sciences-research-fund-25719
 
Description University open day 
Form Of Engagement Activity Participation in an open day or visit at my research institution
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Schools
Results and Impact Discussion around training and careers in microbiology an biomedical science

Inspired about microbiology
Year(s) Of Engagement Activity 2014